Peter G. Harper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peter G. Harper has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Simon Chowdhury
Guy’s Hospital
4 shared publicationsJames F. Spicer
Guy’s Hospital
3 shared publications- Christos Stelios Karapetis
Flinders Medical Centre and Flinders University, Adelaide, SA, Australia
2 shared publications - Desmond Yip
Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia
2 shared publications - James Spicer
King’s College London, Guy’s Hospital, London, UK
2 shared publications A. H. Strickland
Departments of * Medical Oncology. Guy's Hospital Histoputhology London St Thomas' Hospital. London UK
1 shared publication
Latest Publications
- 1 September 2009
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (3) , 149-150
Targets, targeted targets and molecular imaging: new potential treatments, new treatments and new ways of assessing treatments
- 1 September 2009
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (3) , 149-150
Targets, targeted targets and molecular imaging: new potential treatments, new treatments and new ways of assessing treatments
- 1 January 2008
- Published by Springer Nature
- p. 729-743
Effects of rhEPO on quality of life in anemic cancer patients
- 1 January 2008
- Published by Springer Nature
- p. 729-743
Effects of rhEPO on quality of life in anemic cancer patients
- 16 October 2007
- Published by Springer Nature in Targeted Oncology
- Vol. 2 (4) , 235-240
Targeted therapy in hormone refractory prostate cancer
- 16 October 2007
- Published by Springer Nature in Targeted Oncology
- Vol. 2 (4) , 235-240
Targeted therapy in hormone refractory prostate cancer
- 17 November 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 2 (1) , 1-2
Renewed hope in the treatment of renal cell carcinoma
- 17 November 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 2 (1) , 1-2
Renewed hope in the treatment of renal cell carcinoma
- Open Access
- 1 November 2006
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (sup4) , S1-S4
Assessing anaemia and fatigue:putting theory into practice
Anaemia, a frequent complication in patients with cancer, has a major impact on quality of life (QoL). Fatigue is the most debilitating symptom of anaemia, and surveys suggest that 30% of patients with cancer experience fatigue on a daily basis. Patients report that fatigue affects their daily life to a greater extent than nausea, vomiting, diarrhoea, hair loss, depression and pain. Few patients, however, receive treatment or advice about fatigue, and this may reflect an underestimation of the importance of this complication among health professionals. This is despite the availability of a wealth of data confirming that erythropoietic protein therapies can improve the QoL of anaemic patients with cancer, reducing fatigue and improving energy levels. There is a need to improve anaemia management in patients with cancer and this requires a programme of education to promote greater physician awareness of the value of treating anaemia. This article introduces a series of papers based on presentations made at a 2-day meeting entitled Illuminating the World of Anaemia in Cancer – A Global Challenge held in Prague, Czech Republic in May 2006. The following papers discuss the challenges and potential solutions to effective epoetin treatment in patients with cancer, along with prospective novel roles for epoetin.
- 1 November 2006
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (sup4) , S1-S4
Open AccessAssessing anaemia and fatigue:putting theory into practice
Anaemia, a frequent complication in patients with cancer, has a major impact on quality of life (QoL). Fatigue is the most debilitating symptom of anaemia, and surveys suggest that 30% of patients with cancer experience fatigue on a daily basis. Patients report that fatigue affects their daily life to a greater extent than nausea, vomiting, diarrhoea, hair loss, depression and pain. Few patients, however, receive treatment or advice about fatigue, and this may reflect an underestimation of the importance of this complication among health professionals. This is despite the availability of a wealth of data confirming that erythropoietic protein therapies can improve the QoL of anaemic patients with cancer, reducing fatigue and improving energy levels. There is a need to improve anaemia management in patients with cancer and this requires a programme of education to promote greater physician awareness of the value of treating anaemia. This article introduces a series of papers based on presentations made at a 2-day meeting entitled Illuminating the World of Anaemia in Cancer – A Global Challenge held in Prague, Czech Republic in May 2006. The following papers discuss the challenges and potential solutions to effective epoetin treatment in patients with cancer, along with prospective novel roles for epoetin.
- 15 June 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 1 (3) , 172-178
Hypertension and targeted therapy
- 15 June 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 1 (3) , 172-178
Hypertension and targeted therapy
- 12 April 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 1 (2) , 104-108
Hypertension and targeted therapy
- 12 April 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 1 (2) , 104-108
Hypertension and targeted therapy
- 11 April 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 1 (2) , 69-70
Aims and difficulties of targeting
- 11 April 2006
- Published by Springer Nature in Targeted Oncology
- Vol. 1 (2) , 69-70
Aims and difficulties of targeting
- 1 October 2005
- Published by S. Karger AG in Oncology
- Vol. 69 (Suppl. 2) , 2-7
Anaemia of Cancer: Impact on Patient Fatigue and Long-Term Outcome
Anaemia is the most common haematological abnormality encountered by cancer patients. A large European survey of cancer patients (n = 15,367) reported that 67% had anaemia at some point during the survey, and that over 60% of these patients did not receive any treatment for their anaemia. Two other surveys (the FATIGUE surveys) showed that over 75% of cancer patients experienced fatigue at least monthly, with over 30% reporting this symptom on a daily basis. Significantly, patients regarded fatigue as having a greater negative impact on their daily lives than many other cancer- or treatment-related complications, with important emotional and mental consequences including lack of self-motivation, sadness, frustration, and mental exhaustion. Indeed, fatigue was considered so debilitating, 12% of patients felt their quality of life (QoL) was so reduced that they did not wish to continue living. Anaemia is also recognised as an independent predictor of poor prognosis in cancer patients. A systematic review evaluating survival showed a 65% overall increase in the risk of mortality in cancer patients with anaemia. Increasing physicians’ awareness of the importance of effectively treating anaemia in cancer patients therefore has the potential to improve prognosis as well as QoL.
- 1 October 2005
- Published by S. Karger AG in Oncology
- Vol. 69 (Suppl. 2) , 2-7
Anaemia of Cancer: Impact on Patient Fatigue and Long-Term Outcome
Anaemia is the most common haematological abnormality encountered by cancer patients. A large European survey of cancer patients (n = 15,367) reported that 67% had anaemia at some point during the survey, and that over 60% of these patients did not receive any treatment for their anaemia. Two other surveys (the FATIGUE surveys) showed that over 75% of cancer patients experienced fatigue at least monthly, with over 30% reporting this symptom on a daily basis. Significantly, patients regarded fatigue as having a greater negative impact on their daily lives than many other cancer- or treatment-related complications, with important emotional and mental consequences including lack of self-motivation, sadness, frustration, and mental exhaustion. Indeed, fatigue was considered so debilitating, 12% of patients felt their quality of life (QoL) was so reduced that they did not wish to continue living. Anaemia is also recognised as an independent predictor of poor prognosis in cancer patients. A systematic review evaluating survival showed a 65% overall increase in the risk of mortality in cancer patients with anaemia. Increasing physicians’ awareness of the importance of effectively treating anaemia in cancer patients therefore has the potential to improve prognosis as well as QoL.
- Open Access
- 26 July 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (9) , 1055-1062
Targeted therapies for non-small cell lung cancer
Despite recent advances in current chemotherapy, the prognosis for locally advanced and metastatic nonsmall-cell cancer remains poor, and new approaches are required. An increased understanding of the biology of lung cancer has identified pathways mediated by receptor tyrosine kinases as an important target. The epidermal growth factor receptor (EGFR) is frequently expressed on the surface of the lung cancer cell. EGFR can be targeted by inhibitors of receptor tyrosine kinase activity such as erlotinib and gefitinib and by antibodies specific for the extracellular domain. Subset analysis of responders to the receptor tyrosine kinase inhibitors suggests that clinical benefit may correlate with the presence of EGFR mutations. Other drugs in earlier clinical development include those directed against HER-2, VEGF, farnesyl transferase, COX-2 and retinoid receptor.
- 26 July 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (9) , 1055-1062
Open AccessTargeted therapies for non-small cell lung cancer
Despite recent advances in current chemotherapy, the prognosis for locally advanced and metastatic nonsmall-cell cancer remains poor, and new approaches are required. An increased understanding of the biology of lung cancer has identified pathways mediated by receptor tyrosine kinases as an important target. The epidermal growth factor receptor (EGFR) is frequently expressed on the surface of the lung cancer cell. EGFR can be targeted by inhibitors of receptor tyrosine kinase activity such as erlotinib and gefitinib and by antibodies specific for the extracellular domain. Subset analysis of responders to the receptor tyrosine kinase inhibitors suggests that clinical benefit may correlate with the presence of EGFR mutations. Other drugs in earlier clinical development include those directed against HER-2, VEGF, farnesyl transferase, COX-2 and retinoid receptor.